GLP-1 peptides as 'next-gen metabolic' tools: what TikTok gets wrong

What did @kristisawicki actually say?

The creator, who identifies as holding a PhD in molecular and cellular oncology, recommended two compounds she calls "red or tris" — retatrutide and tirzepatide — as her top picks among what she calls "next-gen metabolic peptides." She described them as activating multiple metabolic pathways, improving cellular energy use, reducing inflammation, supporting cardiovascular health through lipid changes, and improving insulin sensitivity and liver function. She positioned retatrutide specifically as "the next generation or GLP3" with an added glucagon receptor target, and tirzepatide as the more established option with longer-term data. The overarching pitch is that these compounds do more than drive weight loss — they support "healthy aging" and longevity. She links to a "peptide cheat sheet" in her bio.

Does the science back this up?

Partially, but with significant caveats the video glosses over. The mechanisms she describes are real. The clinical data, however, is far thinner than the confident tone suggests, especially for retatrutide.

Tirzepatide is a dual GIP/GLP-1 receptor agonist with robust phase 3 data. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed up to 22.5% body weight reduction in adults with obesity. Cardiovascular benefits are supported by the SURPASS-CVOT trial. Improvements in lipid profiles, insulin sensitivity, and liver fat have been documented in peer-reviewed literature. Calling tirzepatide "more established" is accurate.

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 data (Jastreboff et al., 2023, NEJM) showed up to 24.2% weight loss at 48 weeks, which is genuinely impressive. But phase 3 trials are still ongoing. There is no approved indication for retatrutide anywhere in the world as of mid-2025. Framing it as a ready option alongside tirzepatide overstates where the evidence currently sits.

What did they get wrong (or right)?

Let's take these one at a time.

What she got right

• Tirzepatide does work on two pathways (GIP and GLP-1). That is accurate and well-documented.
• Retatrutide does add a glucagon receptor target. This is the mechanistic basis for its potentially greater effect on energy expenditure, and it is consistent with phase 2 findings.
• The cardiovascular signal for tirzepatide is real. Lipid improvements and blood pressure reductions have been observed in trials.
• Describing tirzepatide as having "more long-term data" is correct relative to retatrutide right now.

What she got wrong

• Calling these compounds "peptides" in the wellness sense is misleading framing. These are FDA-regulated prescription drugs (tirzepatide is approved; retatrutide is investigational). Calling them "metabolic signaling compounds" obscures that distinction significantly.
• "GLP3" is not a recognized pharmacological classification. It is informal shorthand used in biohacking communities, not in clinical literature.
• Retatrutide is not available as a legal prescription drug. Framing it as a pick you can simply choose implies access that does not exist through regulated channels.
• The claim that these compounds "reduce internal inflammation" is plausible but not yet robustly proven in humans as a primary endpoint. It is extrapolated from animal data and mechanistic inference.

What should you actually know?

These are not wellness supplements. They are pharmaceutical compounds that carry real risks and require medical supervision.

Tirzepatide (brand names Mounjaro and Zepbound) is FDA-approved and has a defined safety and dosing framework. Common side effects include nausea, vomiting, and gastroparesis risk. It is not appropriate for people with a personal or family history of medullary thyroid carcinoma. The SURMOUNT and SURPASS trial programs give it a legitimate evidence base, but that evidence was built around supervised clinical use, not self-directed biohacking.

Retatrutide has no approved indication anywhere as of mid-2025. The phase 2 data is promising, but phase 2 trials are not the finish line. Eli Lilly is running phase 3 trials now. Until those complete and a regulatory body approves the drug, anyone obtaining retatrutide is getting an unregulated, unverified compound. The purity, dosing accuracy, and safety profile of gray-market versions are unknown.

The "peptide cheat sheet" linked in the creator's bio should be viewed with significant skepticism. Linking educational content to a commercial resource while framing unapproved drugs as personal picks sits in a regulatory gray zone that the FDA has been actively scrutinizing.

Bottom line on @kristisawicki's credentials and framing

A PhD in molecular and cellular oncology is a legitimate research credential, but it does not confer clinical prescribing authority or expertise in endocrinology or metabolic medicine. The science she describes is directionally real but selectively presented. Presenting retatrutide as a compound someone might simply "pick" without flagging its investigational status is the most significant lapse in this video. Informed consent requires more than a disclaimer that this is "not medical advice."